2023 Fiscal Year Final Research Report
Implications of vasohibin-2 expression in human pancreatic cancer and its application to immunotherapy
| Project/Area Number |
21K07232
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
大塚 英郎 東北大学, 大学病院, 講師 (50451563)
石田 晶玄 東北大学, 大学病院, 講師 (90619660)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | vasohibin-2(VASH2) |
|---|
| Outline of Final Research Achievements |
The association of Vash2 expression in primary tumors and liver metastases was investigated using pancreatic cancer cell lines derived from KPC mice.
Vash2-suppressed cell lines were established in KPC cells to establish a mouse model of allogeneic liver metastasis by allogeneic transplantation into the pancreas and splenic injection. In the allogeneic transplantation mouse experiments, the VASH2-suppressed group demonstrated a significant improvement in survival compared to the control group (P = 0.02), underscoring the potential of Vash2 suppression as a therapeutic strategy. In the liver metastasis model mouse experiments, the Vash2 knockdown group demonstrated a significant suppression in the formation of liver metastases compared to the control group (p = 0.03), highlighting the direct impact of Vash2 suppression on metastasis formation.
|
| Free Research Field |
消化器外科
|
| Academic Significance and Societal Importance of the Research Achievements |
膵癌は早期発見が困難で早期に転移をきたし、5年生存率が10%未満である難治癌である。外科切除可能であってもその経過中8割以上が肝転移をきたすため膵癌患者の治療成績向上のためには原発巣ならびに肝転移巣抑制効果の高い新たな治療法の開発が急務である。今回我々はヒト膵癌に近似した自然発がんマウスモデル(KPCマウス) 由来の膵癌細胞株を用い、同種同所移植マウスモデル及び脾臓注による同種肝転移マウスモデルを作成した。Vash2発現抑制群では生存期間の延長効果ならびに肝転移形成の抑制効果を認め、本研究成果からVash2発現抑制による膵癌原発巣および転移巣に対する治療の可能性が示された。
|
